Irinotecan
- PDF / 169,857 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 39 Downloads / 192 Views
1 S
Liver dysfunction following an off-label use: case report In an open-label, multicentre, single arm study of total 55 patients conducted between January 2007 and October 2008, a 52-year-old man was described, who developed liver dysfunction following an off label treatment with drug eluting bead containing irinotecan for liver dominant metastatic colon cancer (MCC). Eventually, he died due to liver dysfunction. The man with liver dominant MCC, had undergone transarterial chemoembolisation (TACE) using drug eluting bead containing irinotecan [DEBIRI; off label use] for unresectable metastases to the liver. Irinotecan-loaded beads were delivered to his right lobe. The treatment consisted of two vials of irinotecan-loaded drug eluting bead containing 200mg of irinotecan (beads measuring 300–500µm). Ondansetron [Zofran] was administered during the procedure, and metronidazole [flaygl] and ciprofloxacin were administered after the procedure. The pain was managed with an epidural. After the procedure, he was hospitalised due to nausea for 3 days. He was discharged without any incident. Twenty-eight days after the procedure, he returned with complaints of nausea. He was diagnosed with liver dysfunction associated with irinotecan [time to reaction onset not stated]. After 30 days, he died due to liver dysfunction. Martin RCG, et al. Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal 803497919 cancer: An interim report. World Journal of Surgical Oncology 7: No. 80, 2009. Available from: URL: http://doi.org/10.1186/1477-7819-7-80
0114-9954/20/1818-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 22 Aug 2020 No. 1818
Data Loading...
